Latest Headlines

Latest Headlines

Shire chief focuses on deal-making, trials with eye to revving up sales

After whetting analysts' expectations on the deal-making front, he executed a series of small deals for experimental ophthalmology treatments--which fit well with his own professional background.

AstraZeneca taps ePharmaSolutions for all-outsourced neuro unit

AstraZeneca is piecing together a team of contractors for its almost virtual neuroscience unit, and the company has signed up with ePharmaSolutions to create a network that will unite its many outsourcers.

Celerion targets biologics, vaccine studies with Irish expansion

Celerion is looking to amp up its share of the biologics and vaccine development markets, launching a new containment room at its Belfast facility that will allow it to compete for study contracts.

New research further reveals nano-gold's delivery potential, safety risk

Gold nanoparticles, because of several inherent characteristics, make excellent drug delivery vehicles, and scientists around the world are now studying the way the tiny particles penetrate cell membranes based on their positive or negative surface charges.

Canada's Medicago reports positive early data for H7N9 vaccine

Global concern is growing over the outbreak of H7N9 avian influenza in China. So far, 133 cases of H7N9 sickness have been confirmed, and at least 37 deaths are deaths are thought to have been caused by the disease.

Bill Gates adds heft and dollars to open R&D

It's one of the latest investments from the Microsoft chairman and world's richest man that focuses on supporting translation of discoveries into breakthroughs for patients.

Aveo investor pins struggling biotech's future on breast cancer study

After starting to gut most of its staff this week, Aveo Oncology has started down a longer path to potential approval of its top drug candidate tivozanib, for which the company no longer plans to develop for kidney cancer.

GlaxoSmithKline investigates alleged data fraud involving R&D lab staffers in China

GlaxoSmithKline has launched a probe of a research study involving its employees from a research lab in Shanghai, China.

Biotech vet Westphal to exit CEO post of cancer drug developer Verastem

Verastem has changed CEOs as the company seeks to translate stem cell discoveries into powerful new cancer drugs. Biotech entrepreneur and Verastem co-founder Christoph Westphal is stepping down from the chief executive post, and president and COO Robert Forrester will take the top job at the company and join the board of directors on July 1.

Bard's drug-coated balloon begins 'below-the-knee' PAD trial

C.R. Bard is working hard to show the versatility of its Lutonix drug-coated balloon, even before it wins FDA approval. A few years after acquiring the technology in a $225 million grab of a company with the same name, the first human patient has joined a new trial testing the device below the knee.